Per Stirling Capital Management’s Bristol-Myers Squibb BMY Stock Holding History

Per Stirling Capital Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-3,153	Closed	-$202K	–	196
2023 Q2	$202K	Buy	3,153 +57	+2%	+$3.82K	0.04%	193
2023 Q1	$215K	Hold	3,096	–	–	0.05%	171
2022 Q4	$223K	Buy	+3,096	New	+$233K	0.04%	190

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Per Stirling Capital Management's BMY Position: Q3 2023 in Review

Per Stirling Capital Management sold out of Bristol-Myers Squibb (BMY) in Q3 2023, closing a stake of 3,153 shares — an estimated $202K sold.

Per Stirling Capital Management first reported a position in BMY in Q4 2022 and held it in 3 quarters. The position peaked at $223K in Q4 2022. 2,387 funds tracked by Wall St. Rank hold BMY as of Q3 2023.

Per Stirling Capital Management reported no remaining Bristol-Myers Squibb position as of Q3 2023 after selling out during the quarter.
Per Stirling Capital Management sold 3,153 Bristol-Myers Squibb shares in Q3 2023, an estimated $202K.
Per Stirling Capital Management first reported a position in Bristol-Myers Squibb in Q4 2022 and held it in 3 quarters.
Per Stirling Capital Management's Bristol-Myers Squibb position peaked at $223K in Q4 2022.
2,387 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2023.

Based on Per Stirling Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.